List of Studies ( Metabolite:Cyanocobalamin)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST003436 | AN005646 | Pharmacokinetics of Fasnall in NSG mice | Blood | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003436 | AN005646 | Pharmacokinetics of Fasnall in NSG mice | Brain | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003436 | AN005646 | Pharmacokinetics of Fasnall in NSG mice | Heart | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003436 | AN005646 | Pharmacokinetics of Fasnall in NSG mice | Liver | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003435 | AN005644 | Metabolomics analysis of zebrafish embryos treated with rotenone, Fasnall, TVB-2640, and GSK2194069 | Media | Zebrafish | Cancer | Wistar Institute | LC-MS |
| ST003434 | AN005642 | Plasma concentrations of Fasnall in mice after a bolus of 10 mg/kg administered intraperitoneally. | Blood | Mouse | Cancer | Wistar Institute | LC-MS |
| ST003433 | AN005640 | Intracellular and medium metabolomics of BT-474 cells treated with dimethylmalonate, Fasnall, and GSK2194069 | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003432 | AN005638 | Intracellular and medium metabolomics of BT-474 cells treated with LW6 | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003431 | AN005636 | Metabolomics analysis of breast cancer cell lines treated with dimethylmalonate (DMM), GSK2194069, and their combination. | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003430 | AN005634 | Intracellular and medium metabolomics of BT-474 cells treated with GSK2194069 | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003429 | AN005632 | Intracellular and medium metabolomics of BT-474 cells treated with Fasnall that was manufactured by Enamine | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003428 | AN005629 | Intracellular and medium metabolomics of BT-474 cells treated with rotenone | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003428 | AN005630 | Intracellular and medium metabolomics of BT-474 cells treated with rotenone | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003427 | AN005627 | Intracellular and medium metabolomics of BT-474 cells treated with dimethylmalonate | Breast cancer cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003427 | AN005628 | Intracellular and medium metabolomics of BT-474 cells treated with dimethylmalonate | Breast cancer cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003412 | AN005605 | Intracellular and medium metabolomics for BT-474 cells treated with cerulenin, TVB-2640, and TVB-3166 for 24 h | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003411 | AN005603 | Intracellular and medium metabolomics for BT-474 cells treated with a range of C75 concentrations for 24 h (C75 MRM included) | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003367 | AN005519 | Intracellular and medium metabolomics for BT-474 cells treated with a range of C75 concentrations for 24 h | Cultured cells | Human | Cancer | Wistar Institute | LC-MS |
| ST003366 | AN005517 | Malate dehydrogenase (MDH) inhibition assay: Fasnall does not affect MDH activity in vitro | Synthetic | Zebrafish | Cancer | Wistar Institute | LC-MS |
| ST002121 | AN003472 | Functional metabolic molecule were identified as novel therapeutic targets to facilitate gemcitabine treatment against pancreatic cancer (Tumor tissues metabolomics) | Tissue | Mouse | Cancer | Shanghai Center for Systems Biomedicine, Shanghai Jiaotong University | LC-MS |
| ST000465 | AN000727 | Uniquely Tumor-Selective Englerin A Profoundly Alters Lipid Metabolism in Renal Cell Carcinoma inducing ER-Stress and an Acute Inflammatory Response | Kidney | Human | Cancer | University of California, San Diego | LC-MS |
